![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, February 28, 2007 10:07:16 PM
I have been thinking about INSM and TRCA's position from DNA's vantage point. I have been lurking around this board and TRCA yahoo board (INSM yahoo mb is worthless!). Everyone makes a big deal about DNA and their strength / influence / lawyers etc. Now I agree DNA is one of "the" bio players, but face it they make so little from TRCA/IGF licensing TRCA/INSM is not even a blip on their radar. No matter what happens to INSM or TRCA it's not going to have much effect on DNA PPS.
But I think DNA may have two concerns when it comes to INSM/TRCA...
1). Potential IP loss - DNA owns the patents and will have little/no stake in any future IGF market without IP. Judge Wilkens could rule against them on IC (or) INSM will most definately appeal, so settlement mitigates this IP risk.
2). Potential longer term erosion / and stagnent HGH franchise - right now IGF isn't a threat to HGH. And one could argue without INSM/BP3 combo IGF may never threaten HGH franchises. But over time as Dr's/patients become more informed of IGF/BP3 possiblities it could erode HGH market for some indications. DNA Nutropin sales were ~380 million last year for DNA. That is only ~5% of DNA's revenue stream and HGH is not going to contribute to revenu growth very much. HGH is a crowded/competitive market. However, IGF is a new related niche growth market (but its too early to tell how market will develop / expand). DNA would like a slice of pie if IGF biology markets becomes a franchise, settlement may open that door to that expansion.
Given these thoughts I wondered, maybe DNA is the party pushing for settlement of some sort. It would reduce risk to their IP, may even get INSM to license their patents (not clear to me if license would go to DNA or TRCA, is TRCA license exclusive?). This also may postion them to wait and see how IGF develops in growth space and position them to make later move thru any license agreement they put in place.
It could be an interesting couple of days, but I'm not sure that this thing won't take more time to play out.
Good luck to all.
Recent INSM News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2024 09:19:37 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 07/05/2024 12:00:00 PM
- Additional Positive Data from Pivotal ASPEN Study of Brensocatib in Patients with Bronchiectasis to be Presented at the 7th World Bronchiectasis Conference • PR Newswire (US) • 07/03/2024 01:03:00 PM
- Insmed Announces Redemption of all $225 Million of Outstanding 1.75% Convertible Senior Notes Due 2025 • PR Newswire (US) • 06/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/13/2024 12:00:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 08:21:15 PM
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • PR Newswire (US) • 06/07/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:23:25 PM
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference • PR Newswire (US) • 06/05/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:00:43 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/03/2024 08:33:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:46:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:44:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/30/2024 09:41:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 09:32:49 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/30/2024 08:15:33 PM
- Insmed to Host Commercial Webinar on June 4, 2024 • PR Newswire (US) • 05/30/2024 08:05:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/30/2024 08:02:27 PM
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock • PR Newswire (US) • 05/30/2024 12:00:00 PM
- Insmed Announces Proposed $500 Million Public Offering of Common Stock • PR Newswire (US) • 05/28/2024 10:21:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:51:26 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:49:20 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/28/2024 08:47:36 PM
Peer To Peer Network aka Mobicard™ Launches AI Investor Chatbot Boosting Engagement & Lead Generation on Ihub • PTOP • Jul 15, 2024 8:30 AM
Greenlite Ventures Announces AI Integration into No Limit Platforms • GRNL • Jul 15, 2024 8:00 AM
Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • BLO • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM